Medicare to boost payment for certain diagnostic imaging agents
Radiology Business
NOVEMBER 5, 2024
CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.
Diagnostic Imaging Imaging Radiopharmaceuticals 
Targeted radiopharmaceuticals offer new hope for longer 'healthspans'
AuntMinnie
MARCH 15, 2024
An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.
Join 5,000
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
The rise of theranostics: Part 5 -- Advice from center administrators
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.
Nuclear Medicine 
264
264 
The rise of theranostics: Part 3 -- What is a theranostics center?
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Nuclear Medicine 264
264 
Meet the Minnies 2024 finalists
AuntMinnie
OCTOBER 25, 2024
7-tesla MRI gets us closer in imaging to our pathology colleagues, and offers many new possibilities for better treatment," he said. Going forward, Middlebrooks plans to apply his skills to the further development of AI for image reconstruction. There's a huge role for AI in image acquisition," he said. Perry Pickhardt, MD.
Nuclear Medicine 358
358 
FDA fast-tracks Clarity’s prostate cancer treatment
AuntMinnie
FEBRUARY 19, 2025
Food and Drug Administration (FDA) for its copper-67 (Cu-67) SAR-bisPSMA radiopharmaceutical for treating advanced prostate cancer. The classification builds on Clarity's earlier receipt of fast-track designation for its PET diagnostic imaging agent Cu-64 SAR-bisPSMA for identifying patients with the disease.
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
Imaging Technology
DECEMBER 6, 2023
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
Diagnostic 105
105 
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
Imaging Technology
APRIL 10, 2024
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Diagnostic Imaging
NOVEMBER 15, 2024
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer
Imaging Technology
JULY 9, 2024
Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. “I Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Bracco Imaging S.p.A., Bracco Imaging S.p.A.,
Diagnostic 105
105 
A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging
Diagnostic Imaging
JUNE 28, 2023
In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,
Radiometals for diagnostic imaging and theranostics
Open Medscience
AUGUST 8, 2019
Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnostic imaging and theranostics appeared first on Open Medscience.
Generative AI, radiologist shortages feature in 2024 Minnies
AuntMinnie
NOVEMBER 12, 2024
His lab team is currently focused on "implementing advanced techniques, such as parallel transmit, to achieve more consistent image quality and fully harness the power of 7T for every patient," Middlebrooks said. Avoiding certain sequences due to difficulties at 7T is not always practical.
Radiologist 360
360 
Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award
Imaging Technology
JUNE 10, 2024
The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.
Nuclear Medicine 104
104 
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
Diagnostic Imaging
JANUARY 24, 2025
In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
Imaging Technology
APRIL 3, 2023
produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.
Medical 98
98 
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
Imaging Technology
MAY 30, 2023
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Conventional imaging techniques such as CT and MRI are limited in the information they may provide.
Diagnostic 97
97 
Patent Battle Brewing Between Novartis, Lantheus Over Generic Lutathera Radioligand Therapy
Diagnostic Imaging
JANUARY 12, 2024
The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.
Diagnostic 98
98 
Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer
Imaging Technology
JUNE 29, 2023
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.
Clinic 98
98 
What is Radiotheranostics? The Future of Personalised Cancer Diagnosis
Open Medscience
JUNE 22, 2024
Radiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.
Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications
Open Medscience
SEPTEMBER 25, 2024
Radiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness. The post Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications appeared first on Open MedScience.
Clinic 52
52 
Visit TTG Imaging Solutions at ICE 2022
TTG Imaging Solutions
FEBRUARY 17, 2022
Imaging Conference & Expo: February 20 – 22, 2022 TTG Imaging Solutions will be exhibiting at the Imaging Conference & Expo in Napa, CA. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook. Learn more about TTG in our video overview.
The Future of Radiotheranostics: A New Frontier in Precision Medicine
Open Medscience
SEPTEMBER 14, 2024
Radiotheranostics offers a precise, personalised approach to cancer treatment by combining diagnostic imaging with targeted therapy The post The Future of Radiotheranostics: A New Frontier in Precision Medicine appeared first on Open MedScience.
FDA Grants Fast Track Designation to 64Cu-SAR-bisPSMA PET Agent for Prostate Cancer
Diagnostic Imaging
AUGUST 23, 2024
Currently in phase III trials, the 64Cu-SAR-bisPSMA PET agent reportedly offers a longer half-life and higher tumor uptake than other radiopharmaceuticals for prostate cancer imaging.
Visit TTG Imaging Solutions at ASTRO 2021 Annual Meeting
TTG Imaging Solutions
OCTOBER 20, 2021
The American Society for Radiation Oncology 2021 Annual Meeting: October 24 – 26 TTG Imaging Solutions is proud to be exhibiting at the American Society for Radiation Oncology Annual Meeting in Chicago, IL. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.
Visit TTG Imaging Solutions at ASNC 2021 Virtual Annual Meeting
TTG Imaging Solutions
SEPTEMBER 28, 2021
The American Society of Nuclear Cardiology 2021 Virtual Annual Meeting: September 30 – October 2 TTG Imaging Solutions is proud to be a Bronze Sponsor at the American Society of Nuclear Cardiology Virtual Annual Meeting. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.
Visit TTG Imaging Solutions at ASNC 2022 Cardiac PET Intensive Virtual Workshop
TTG Imaging Solutions
JANUARY 9, 2022
The American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop: Jan 14 – 16, 2022 TTG Imaging Solutions is proud to sponsor the American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.
Visit TTG Imaging Solutions at ASNC 2021 Cardiac PET Workshop
TTG Imaging Solutions
OCTOBER 27, 2021
The American Society of Nuclear Cardiology Cardiac PET Advanced Virtual Workshop – Oct 30 & 31, 2021 TTG Imaging Solutions is proud to be a Bronze Sponsor at the American Society of Nuclear Cardiology Cardiac PET Advanced Virtual Workshop. Request a meeting with one of our Regional Sales Managers at sales@ttgimagingsolutions.com.
New SNMMI President Cathy Cutler, PhD Discusses Current Challenges and Goals for Nuclear Medicine
Diagnostic Imaging
JUNE 9, 2024
shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,
PET Agent Receives FDA Fast Track Designation for mCRPC
Diagnostic Imaging
FEBRUARY 19, 2025
The PET radiopharmaceutical SAR-bisPSMA has garnered three FDA fast track designations in a six-month period for use in the detection and management of prostate cancer.
Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer
Imaging Technology
JULY 28, 2023
It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. Chief Medical Officer of Blue Earth Diagnostics. POSLUMA was approved by the U.S.
Diagnostic 98
98 
TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings
TTG Imaging Solutions
MAY 5, 2023
Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.
Imaging 52
52 
TTG Imaging Solutions, LLC Announces Executive Leadership Changes
TTG Imaging Solutions
NOVEMBER 1, 2021
PITTSBURGH, PA (November 1, 2021) – TTG Imaging Solutions, LLC (TTG) announced today executive leadership changes that will drive the company’s next phase of growth following its 9th acquisition in 2 years of Medical Imaging Technologies, an Akron, Ohio based nuclear medicine equipment and service organization.
FDA Clears Automated Dosimetry with the Monte Carlo Method for Radionuclide Therapy
Diagnostic Imaging
OCTOBER 4, 2024
The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.
GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24
Imaging Technology
JUNE 20, 2024
More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging.
Healthcare 104
104 
Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)
Future Teleradiology
NOVEMBER 27, 2023
This blog post sheds light on recent breakthroughs in nuclear medicine, illuminating the innovative advancements that are shaping the future of medical imaging and treatment. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.
Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
Breaking Ground: Exploring the Latest Innovations in the Field of Nuclear Medicine (Madhya Pradesh, Bhopal, Raisen, Rajgarh, Sehore, Vidisha, Morena, Sheopur, Bhind, Gwalior, Ashoknagar)
Future Teleradiology
NOVEMBER 21, 2023
This blog explores the latest innovations in nuclear medicine, shedding light on cutting-edge technologies and breakthroughs that are reshaping the landscape of medical imaging and treatment. Highlight how this field merges principles of physics with medical applications for both diagnostic and therapeutic purposes.
Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer
Open Medscience
JUNE 22, 2024
Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.
Diagnostic 52
52 
Cancer Radiotheranostics: The Future of Targeted Cancer Therapy
Open Medscience
OCTOBER 19, 2024
Cancer radiotheranostics combines targeted radiotherapy and diagnostic imaging to provide personalised, precise, and effective cancer treatment. The post Cancer Radiotheranostics: The Future of Targeted Cancer Therapy appeared first on Open MedScience.
What Does It Take to Become a Radiologist?
TRA Medical Imaging
JANUARY 17, 2025
Radiologists are medical doctors who specialize in interpreting imaging studies like X-rays, CT scans, MRIs, and ultrasounds to diagnose and guide treatment for various conditions. This rigorous training covers all imaging modalities, from X-rays to advanced techniques like MRI and PET/CT scans.
Radiologist 52
52 
Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO
Imaging Technology
OCTOBER 5, 2023
Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. on behalf of Gary A.
Diagnose 52
52 
Let's personalize your content